Clinical trials: Multiple-drug Resistance
Bacterial Infection, Multiple-drug Resistance
Intravenous Fosfomycin Pharmacokinetics Study
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window).
- Conditions
- Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance
- Trial name
- NCT03910673
- Testing
- Fosfomycin disodium
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multidrug Resistant Klebsiella Pneumoniae Infection
Phenotypic and Genotypic Detection of Biofilm Formation and Efflux Pump Activity in Multi-drug Resistant Klebsiella Pneumoniae
1. Sample: urine, pus and sputum samples. 2. Culture: the samples will be inoculated on the MacConkey agar and subcultured on eosine methylene blue agar. 3. Identification of isolates will be done by: Colony morphology.
- Trial name
- Klebsiella (NCT07541690)
- Testing
- Genotypic Detection of Biofilm Formation and Efflux Pump Activity.
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Drug Interactions
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Researchers in this study want to learn how the study drug BAY1817080 interacts with another drug called rosuvastatin (brand name: Crestor) and affects the way the body absorbs, distributes and excretes rosuvastatin in healthy…
- Trial name
- NCT04252300
- Testing
- Rosuvastatin, Rosuvastatin + BAY1817080
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Multi-drug Resistant Tuberculosis
Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
India has the highest incidence of and mortality from multi-drug resistant tuberculosis (MDR-TB) globally. Vitamin D status may be an important determinant of MDR-TB infection and treatment outcomes; however, observational…
- Trial name
- NCT04342598
- Testing
- Serum Vitamin D
- Where
- India
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
HIV/AIDS
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir
The objectives of this data collection activity are to: 1. Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on…
- Trial name
- NewHorizon (NCT04194021)
- Where
- 5 sites in Cameroon, Eswatini and 3 more
- Volunteers
- 871 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Drug Resistance, Multiple, Travel Medicine
The Effect of Hand Hygiene on Colonization Rates With Multidrug Resistant Enteric Pathogens in Travellers
Travelling to tropical and subtropical countries is a known risk factor for becoming colonized with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.
- Trial name
- NCT03306407
- Testing
- Improved hand hygiene
- Where
- 2 sites in Switzerland
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Christoph Hatz
Healthy Adult Participants
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
The objective of this study is to evaluate the effect of multiple doses of vorasidenib on single-dose PK of bupropion as an index substrate of CYP2B6, flurbiprofen as an index substrate of CYP2C9, omeprazole as an index substrate…
- Trial name
- NCT07235748
- Testing
- Vorasidenib, Bupropion, Flurbiprofen
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Multi-drug Resistant Tuberculosis
Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.
- Trial name
- TB-MR (NCT03057756)
- Testing
- Km+ Mfx+ Pto + H + Cfz +E+Z
- Where
- Gabon
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Klebsiella Pneumoniae Pneumonia
Fecal Microbiota Transplantation in Patients With Multiple Drug Resistant Klebsiella Pneumoniae Pneumonia
Multidrug-resistant Klebsiella pneumoniae (MDR-KP) infections account for 10% of all nosocomial infections, and even with effective antibiotics, the mortality rate is as high as 50%.
- Trial name
- NCT06641778
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- luxia Kong
Multidrug-resistant Tuberculosis (MDR-TB)
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures.
- Trial name
- MESTCAR (NCT07017803)
- Where
- 8 sites in Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Pulmonary Disease, Tuberculosis, Pulmonary
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis
- Trial name
- NCT05526911
- Testing
- TBAJ-876, Midazolam, Digoxin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
TB Multi-drug Resistant
Dose Escalation Study of SQ109 in Healthy Adult Volunteers
The purposes of this study are to determine: how safe it is to take SQ109 (an experimental tuberculosis treatment) once a day by mouth for up to 2 weeks in 2 different dosages; how well the body accepts it; how SQ109 enters and…
- Trial name
- NCT00866190
- Testing
- SQ109
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Urinary Tract Infections, Recurrent UTI
Probiotics and Multi-Drug Resistant Urinary Tract Infection
This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI).
- Conditions
- Urinary Tract Infections, Recurrent UTI, Antibiotic Resistant Infection
- Trial name
- NCT03644966
- Testing
- Bifidobacterium infantis, Antibiotics
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ochsner Health System
Breast Cancer
Pilot Study of 18F Fluoropaclitaxel (FPAC)
Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients. MDR refers to a phenotype whereby a tumor is resistant to a large number of natural chemotherapeutic drugs.
- Trial name
- NCT00572598
- Testing
- 4- [F-18] fluoropaclitaxel
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Tuberculosis, MDR
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among…
- Trial name
- PHOENIx MDR-TB (NCT03568383)
- Testing
- Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
- Where
- 31 sites in Botswana, Brazil and 11 more
- Volunteers
- 5,832 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multi Drug Resistant Department, Multi Drug Resistant Bacteria
Testing Carriage of Resistant Bacteria Using Swabs on Surfaces and Staff in a Complex Nursing Unit for Patients with Resistant Bacteria
Impact of Care Team and Surfaces on the Spread of Resistant Bacteria in a Specialized Complex Nursing Unit for MDR Pathogen Carriers Background Multi-drug resistant (MDR) bacteria present a severe clinical and epidemiological…
- Trial name
- NCT06696144
- Testing
- Skin swabs for multi drug resistant bacteria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shmuel Harofeh Hospital, Geriatric Medical Center
Multidrug Resistance
Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel
Acquisition and transmission of MDROs in healthcare facilities is a major patient safety problem, afflicting in particular the antibiotic-exposed and immunodeficient patient populations.
- Trial name
- NCT01952158
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E)
Household Transmission Dynamics of Multidrug Resistant Enterobacterales
The HOME study will prospectively follow a cohort of Multi-Drug Resistant Enterobacterales (MDR-E) carriers after hospital discharge, and their related household members over a 3-month period.
- Trial name
- HOME (NCT05798364)
- Where
- France
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aging, Aging Well
100-Year Human Aging Study
The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo…
- Conditions
- Aging, Aging Well, All-Cause Mortality, Mortality
- Trial name
- NCT07563777
- Testing
- Comprehensive Multi-System Clinical Screening
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Longevity Metrics, Inc.
Healthy
TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam
This study comprises 2 cohorts, and in each cohort, the study will be conducted as an open-label add-on study. The purpose of the study is to investigate the pharmacokinetics of each substrate in concomitant administration of a…
- Trial name
- NCT03043248
- Testing
- TRK-700, Digoxin, Midazolam
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Toray Industries, Inc